news.cision.com

Sandvik has completed the previously announced acquisition of 67% of Chuzhou Yongpu Carbide Tools Co., Ltd, a China based premium solid round tools company, with a call option to buy the remaining part in three years’ time. The company had revenues of approximately SEK 400 million for the twelve month period Q2 2020 to Q1 2021, an EBIT margin slightly dilutive to Sandvik Manufacturing and Machining Solutions. Impact on earnings per share will initially be neutral. The company will be reported in Sandvik Coromant, a division within Sandvik Manufacturing and Machining Solutions.

Strong growth, profit suppressed by cost overruns at one site

DELETE GROUP OYJ Interim Financial Statements January–June 2021 (IFRS, IAS 34, unaudited) STRONG GROWTH, PROFIT SUPPRESSED BY COST OVERRUNS AT ONE SITE Demolition Services is reported in this report in accordance with IFRS 5 “Assets Held for Sale and Discontinued Operations” and is not included in the financials for continuing operations. More information is available in the notes section. KEY POINTS: APRIL–JUNE 2021 · Net sales increased by 48% to EUR 41.7 (Q2 2020: 28.1) million · EBITDA increased by EUR 1.2 million to EUR 3.5 (2.3) million · EBIT increased by EUR 1.

Midsona strengthens its position in Finland through acquisition

Midsona AB (publ) has today entered into an agreement to acquire all shares in the Finnish company Vitality and Oy (Vitality), a leading provider in consumer health. The purchase price amounts to approximately SEK 116 million (EUR 11.4 million) on a debt-free/cash-free basis. Closing is planned to take place October 1, 2021.Midsona's ambition is to continue to consolidate the market in the Nordic region through acquisitions in accordance with the company's growth strategy. The acquisition of Vitality will strengthen Midsona's position in Finland through its broad product portfolio in

New development of the IndiTreat® technology allows prediction of response to anti-angiogenic drugs in colorectal cancer.

Fri, Aug 20, 2021 10:50 CET

2cureX is proud to announce that it has been able to predict response to anti-angiogenic drugs with a modified version of its IndiTreat® technology. The development could be the basis for a new product addressing this drug class. The results have been published together with Rigshospitalet, Bispebjerg Hospital, University of Copenhagen and University of Bristol.Solid tumors require an increased consumption of oxygen and nutrients to grow and spread. In order to get this extra inflow, tumors create new blood vessels and hijack existing ones, a process called angiogenesis. It is proven that,

Flowscape receives expansion order in Switzerland

Flowscape continues its expansion in Switzerland, this time with an existing customer who is expanding its room booking solution to a new office. The order was completed together with a local partner. The total order value amounts to SEK 310,000, with SEK 115,000 as annual revenue.With this additional order added to existing installations for the customer, the total license revenue amounts to SEK 245,000 per year. The customer has several offices around Switzerland and Flowscape sees great opportunities for additional installations in the future. “We are pleased to see that we continue

Profitable growth and advanced market positions

Fri, Aug 20, 2021 10:00 CET

April – June 2021 · Net sales amounted to SEK 490.5 (217.0) million · Adjusted EBIT increased to SEK 46.6 (18.0) million and adjusted EBIT margin amounted to 9.5 (8.3) % · Operating profit (EBIT) increased to SEK 36.2 (12.2) million and EBIT margin amounted to 7.4 (5.6) % · Profit for the period amounted to SEK 19.6 (5.2) million “The Group’s three segments have developed very satisfactorily during the second quarter with strong growth and record profitability in parts of the Group. We also continue to be active in the consolidation of our industry and have completed three

Nordisk Bergteknik is intensifying its efforts to review the capital structure

Fri, Aug 20, 2021 09:55 CET

Since the fourth quarter of 2020, Nordisk Bergteknik has been working on a strategic review of the Company's capital structure. In connection with a possible listing of the Company's shares, the Company intends to change its current capital structure. The intended change relates to the Company's outstanding corporate bonds of SEK 400 million, which in the event of a listing are intended to be replaced by bank financing. A decision regarding a possible listing of the shares and a change in the capital structure is expected to be made during the current year. The Company will primarily use

Holmström Fastigheter Holding’s subsidiary F Holmström Holding 6 AB completes the public offer to the shareholders of Magnolia Bostad

Fri, Aug 20, 2021 09:40 CET

F Holmström Holding 6 AB, reg.no. 559279-7376 (“FHH”), a company which together with inter alia Holmström Fastigheter Holding AB (publ), reg.no. 559286-6809 (“Holmström Holding”) is included in Holmströmgruppen, announced on 7 July 2021 a recommended cash offer to the shareholders of Magnolia Bostad AB, reg.no. 556797-7078 (“Magnolia Bostad” or “the Company”) to tender all of their shares in Magnolia Bostad to FHH (the “Offer”). FHH has announced today that the Offer has been accepted to such an extent that FHH holds more than 90 per cent of the shares in Magnolia Bostad and has further

NPRO: Extraordinary general meeting completed

Fri, Aug 20, 2021 09:30 CET

Reference is made to the stock exchange notice on 16 August 2021, regarding the compulsory acquisition of all shares in Norwegian Property ASA ("Norwegian Property") not already owned by Geveran Trading Co. Limited. Following the compulsory acquisition, Norwegian Property has today, 20 August 2021, held an extraordinary general meeting. All resolutions were unanimously approved, including, inter alia, the resolution to apply for delisting of the shares in Norwegian Property from the Oslo Stock Exchange. Accordingly, Norwegian Property will apply for a delisting of its shares from the

Arctic Bioscience AS: Invitation to Presentation of H1 2021 Results

Fri, Aug 20, 2021 09:08 CET

Arctic Bioscience AS will publish its financial results for the first half of 2021 onThursday August 26, 2021, at 07:00 CEST. The company will host a webcastpresentation of the results the same day at 08:30 CEST.Arctic Bioscience AS H1 2021 webcast presentation:Date: Thursday August 26, 2021Time: 08:30 a.m. CESTFormat: Webcast and Q&ALanguage: EnglishLink: https://streams.eventcdn.net/arcticbioscienceas/financial-results-first-half-2021/registerThe H1 2021 report and presentation will be made available at www.arctic-bioscience.comand on the Euronext Growth company page (

Norway Royal Salmon ASA (NRS): SalMar intends to launch a voluntary cash offer to acquire all outstanding shares in Norway Royal Salmon

Fri, Aug 20, 2021 09:01 CET

This is a copy of the stock exchange announcement from Salmar ASA at 08:50 today. Frøya, 20 August 2021 · Voluntary cash offer to acquire all outstanding shares in Norway Royal Salmon for NOK 270 per share · The Offer values the Company at approximately NOK 11,764 million and represents a 12.5% premium to the NTS offer and a premium of 54.0% to the 30 trading day VWAP of the NRS share prior to the date for the NTS offer · With several overlapping industrial interests, both in Northern Norway, the West Fjords of Iceland, and offshore, a combination offers ample opportunities to

NENT Group restarts Nordic action thriller ‘The Machinery’ for second season

· Kristoffer Joner (‘The Revenant’; ‘Mission: Impossible – Fallout’) reprises starring role in new season · Season one set viewing records on NENT Group’s Viaplay streaming service · NENT Group to premiere at least 50 original productions in 2021 Nordic Entertainment Group (NENT Group) and Norwegian superstar Kristoffer Joner (Hollywood’s ‘The Revenant’; ‘Mission: Impossible – Fallout’) will reunite for a new season of the hit Viaplay Original ‘The Machinery’. The first season of the high-tempo Nordic action thriller series broke viewing records on NENT Group’s Viaplay streaming

P CAPITAL PARTNERS IV ISSUES NEW DEBENTURES

P Capital Partners IV AB (publ) today announces that on 3 September 2021, the company will increase its contributed capital by EUR 15.4 million through the issuance of 154,240 series A1 participation loan debentures at a price of EUR 100 each and by an equity contribution of EUR 0.06 million. The new debentures will be eligible for coupon payments from the fourth quarter 2021. Including the newly issued debentures, P Capital Partners IV’s funding amounts to EUR 166.4 million comprised of series A1 participation loan debentures of EUR 165.8 million and EUR 0.6 million in equity. P

P CAPITAL PARTNERS IV B ISSUES NEW DEBENTURES

P Capital Partners IV B AB (publ) today announces that on 3 September 2021, the company will increase its contributed capital by EUR 49.1 million through the issuance of 216,400 series A1 and 20,000 series A2 participation loan debentures at a price of EUR 100 each and 25,500 series B participation loan debentures at a price of EUR 1,000 each and by an equity contribution of EUR 0.18 million. The new debentures will be eligible for coupon payments from the fourth quarter 2021. Including the newly issued debentures, P Capital Partners IV B’s funding amounts to EUR 530.2 million

Gradientech: Interim report January 1 - June 30, 2021

Gradientech AB (publ) interim report for Q2 2021 is now available on the company's website www.gradientech.se.Second quarter April-June 2021 · Net sales amounted to 2 KSEK (21 KSEK). · Net loss amounted to SEK -11,516 KSEK (-8,641 KSEK). · Earnings per share were SEK -0.94 (SEK -0.98). · Cashflow from operating activities totalled -10,857 KSEK (-10,389 KSEK). · As of 30 June 2021, cash and cash equivalents totalled 43,995 KSEK (14,297 KSEK). · As of 30 June 2021, equity amounted to 53,668 KSEK (17,340 KSEK). · An external audit (bsi) of the company's ISO13485-

Interim report January-June 2021

Fri, Aug 20, 2021 08:51 CET

Continued strong growth in the second quarter of the year. New acquisition with a strong base and solid establishment in the south of Sweden and a significant increase in net sales, despite continued challenges linked to resource and competence supply in an expansive market.“Like the first quarter of the year, the second quarter has shown solid growth. We welcomed Norrvidinge into the Bellman Group, which has established a strong base for Bellman Group in the south of Sweden. The quarter shows a significant increased Group net sale (SEK 662.2 million), an increase of 45.7 percent compared

TriHealth Good Samaritan Hospital choose WasteLog®

Pharmacolog’s partner, Codonics, to deliver leading Ohio hospital with WasteLog® to assist with drug diversion prevention initiative.Codonics, the exclusive U.S. distributor of WasteLog®, is helping U.S. hospitals reduce the potential threat of drug diversion with WasteLog®, a drug assay device that helps eradicate diversion. The company placed an order for a WasteLog® system which will be installed at TriHealth Good Samaritan Hospital, the oldest and largest private teaching and tertiary healthcare facility in Greater Cincinnati, Ohio, and part of one of the most integrated healthcare

Greenfood acquires the premium supplier Lundgrens primörer

Fri, Aug 20, 2021 08:43 CET

Greenfood acquires 100 percent of the ownership in fruit and vegetable specialist Lundgrens primörer. A company on Sweden's west coast, Lundgren's has a turnover of almost 90 million SEK. It is known for its wide range consisting of premium fruits, vegetables and processed raw materials of the highest quality."Through the purchase of Lundgren's, we become a nationwide supplier. We are expanding the quality range further and making their fantastic products available to customers and consumers around Sweden," said Ted Stenshed, CEO of the Greenfood Fresh Produce business area. Greenfood

FluoGuide receives tranche of EUR 750,000 under its ongoing grant from EIC Accelerator - SME Instrument under European Union for FG001

Fri, Aug 20, 2021 08:35 CET

Copenhagen, Denmark, 20 August 2021 FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce that the Company has received a tranche of EUR 750,000 as pre-financing under the total grant of EUR 2.5 million (approx. DKK 18.6 million or SEK 26.1 million) from the European Innovation Council (EIC) following their twelve-month review of the development of FG001.Last year, the Company announced it was awarded with a grant on in total EUR 2.5 million under the European Innovation Council (EIC) for the purpose of funding both manufacturing (CMC) and clinical work supporting Phase III

Cown Energy AB: Half-year Report January-June 2021

Q2 – april-june 2021 · Revenue amounted to SEK 5,683 thousand (8,247). · Operating loss amounted to SEK -8,461 thousand (24). · Net financial items amounted to SEK 5,925 thousand (19,676). · Unrealised changes in property values amounted to SEK -5,891 thousand (-2,529). · Result before tax amounted to SEK -8,426 thousand (17,171), and result after tax amounted to SEK -8,669 thousand (13,730), corresponding to SEK -0.02 (0.03) per share. H1 – january-june 2021 · Revenue amounted to SEK 10,562 thousand (17,355). · Operating loss amounted to SEK -11,770 thousand (

Paulig invests in next generation fats for plant-based foods

Paulig’s venture arm PINC has invested in Swedish start-up Melt&Marble, which has developed yeast as a production platform for tasty and sustainable fats for plant-based foods. Melt&Marble has raised EUR 750k in seed funding to finalise its prototype and strengthen the team. Paulig’s product range is almost 100% plant-based, and as a sustainability frontrunner, the company actively seeks innovative products that are good for both people and the planet. Melt&Marble uses precision fermentation to produce sustainable fats for plant-based foods. By engineering the metabolism of yeasts,

INITIATOR PHARMA: INTERIM REPORT JANUARY- JUNE 2021

Financial Highlights Initiator Pharma A/S is a Danish registered company, and is reporting its financial situation in Danish kroner (DKK). Initiator Pharma A/S was registered on May 2, 2016. Second Quarter (2021-04-01 – 2021-06-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -4,944 (-3,013) · Earnings per share was DKK –0.14 (-0.13) First Six Months of the Year (2021-01-01 – 2021-06-30) · Net revenues were TDKK 0 (0) · EBIT was TDKK -6,736 (-5,405) · Earnings per share was DKK –0.19 (-0.23) · Cash and bank: TDKK 31,099 (8,189) · Solidity:

ORGANOCLICK AB (PUBL) PUBLISH INTERIM REPORT FOR Q2 2021